Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.

The conversation is about using valproic acid, an anti-seizure medication, as a topical treatment to promote hair growth. The original poster is seeking personal experiences from those who have tried this method.

Treatments for hair loss, including microneedling (dermarolling and dermapen) and the use of minoxidil, finasteride, and RU58841. It provides detailed information about cost and usage of the various treatments, as well as potential side effects.

A user reported hairline regrowth after two weeks on a treatment including finasteride, peppermint and rosemary oils, emu oil, magnesium oil spray, apple cider vinegar, and dermarolling, while avoiding shampoos and conditioners. They believe DHT contributes to hair loss but also suggest follicle fibrosis is an issue.

Microneedling can be effective for hair regrowth, especially when used with oils like castor, emu, and rosemary, but should be done with caution regarding needle size and frequency. Some users avoid minoxidil due to its side effects and cost, opting for alternatives like rosemary oil.

Injections of follistatin and growth factors can improve hair growth. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

The conversation discusses unconventional methods for hair regrowth, including scalp trauma like burning or microneedling, and compares them to treatments like Minoxidil and Finasteride. It highlights skepticism about these methods and the body's unpredictable healing responses.

Japanese scientists discovered ABM cells, enabling successful human hair follicle cloning, potentially curing hair loss. The treatment may be available in Japan by 2028, but it will be expensive and require travel.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.

PP405 is a promising hair growth stimulant but not a cure for advanced hair loss, as it may only help dormant follicles. Treatments like Minoxidil, Finasteride, and Dutasteride are discussed, with emphasis on early intervention for effectiveness.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.

Hair loss research is important and contributes to overall scientific advancement, benefiting emotional well-being and potentially aiding other medical fields. Treatments mentioned include PP405 and SCUBE3.

AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.

The conversation is about restoring hairline and temples using finasteride, micro-needling, and Ketoconazole shampoo, with suggestions to add minoxidil despite its side effects. A hair transplant is considered likely necessary for significant restoration.

Avoid burning or scarring the scalp for hair growth; instead, use treatments like finasteride, minoxidil, or consider a hair transplant. Microneedling should be done carefully, and extreme methods can cause harm.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

Switching from finasteride to dutasteride for hair loss treatment, with concerns about dosage and potential shedding. Users suggest maintaining minoxidil dosage and possibly transitioning gradually to avoid hair loss.

Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.